William Cornwell, MD
Advanced Heart Failure and Transplant Cardiology · Aurora, CONPI 1235392853
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,660 of the $25,036 with a category attached, or 70.5%. Merck accounts for 77.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $19,479 and has fallen 99.1% since, to $170 in 2024.
Across 56 payments — averaging $447.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$19K
- Medtronic$4K
- Edwards Lifesciences$1K
- Abbott$345
Across 10 payments — averaging $30,511 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$252K
- Medtronic$53K
What the payments were for
- Consulting fees$17,66071%
- Travel & lodging$5,49822%
- Food & beverage$1,8788%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 22 | $19,479 |
| Medtronic(2 entities) | 29 | $4,212 |
| Edwards Lifesciences | 1 | $1,000 |
| Abbott | 4 | $345 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartWare HVAD$3,358
- CARDIOMEMS$170
- Assurity Pacemaker$128
How this compares
Too few advanced heart failure and transplant cardiology providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 34 | $43,773 |
| XareltoRivaroxaban | 16 | $12,767 |
| Metoprolol Succinate | 31 | $415 |
| Losartan Potassium | 34 | $408 |
| Carvedilol | 22 | $272 |
| Digoxin | 12 | $269 |
| Pravastatin Sodium | 12 | $237 |
| Furosemide | 28 | $209 |
| Spironolactone | 19 | $173 |
| Atorvastatin Calcium | 17 | $173 |
| Rosuvastatin Calcium | 11 | $92 |
| Lisinopril | 14 | $38 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Aurora
- Josephine HarringtonAurora$119K
- Larry AllenAurora$31K
- Andreas BriekeAurora$14K
- Christine SailerAurora$10K
- Amrut AmbardekarAurora$3K
- Benjamin KopeckyAurora$702
- Natasha AltmanAurora$210
- Prateeti KhazanieAurora$122
- Shelley MiyamotoAurora$0
- Aaron EmmonsWheat Ridge$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.